Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are willing and able to follow all study rules and attend all required visits for the full length of the study
- You are able to swallow pills and are willing to stick to the study medication schedule
- You have been diagnosed with Acute Myeloid Leukemia (AML) using current recognized medical standards, and you received your first round of treatment (induction therapy) with either: (a) a drug called 5-Azacitidine (given as an injection under the skin) combined with Venetoclax, or (b) a drug called Decitabine (given through a drip/IV) combined with Venetoclax
- Your AML went into remission (less than 5% abnormal cells in your bone marrow) within 3 treatment cycles, confirmed by a bone marrow biopsy
- You are able to give your consent to join the trial within roughly 10 days of receiving your bone marrow biopsy results showing remission, and be ready to start the trial within roughly 10 days of those results
- Your general health and ability to carry out daily activities falls within an acceptable range (confirm with trial site)
- You are not suitable for, or have chosen not to have, intensive treatment or a stem cell transplant
- You are able to understand and sign the consent forms and other study documents
- At the time you start the trial, your blood counts (white blood cells, platelets, and haemoglobin) have recovered to acceptable levels without needing a blood transfusion in the past 7 days
- You have not received a blood cell growth-boosting injection (G-CSF) in the 14 days before starting the trial
Who may not be able to join:
- You are currently taking part in another clinical trial involving an experimental drug
- You have received a growth-boosting injection (G-CSF) within the 14 days before starting the trial
- You are currently taking certain targeted cancer drugs, such as FLT3 inhibitors or IDH1/2 inhibitors (confirm with trial site)
- Before your first round of AML treatment, you had already received: a hypomethylating agent or a BCL-2 inhibitor drug for AML or a related blood condition (MDS); a type of immune cell therapy called CAR-T; or any experimental drug within 14 days before joining the study
- You have a specific subtype of leukemia called Acute Promyelocytic Leukemia (APL) with a particular genetic change called t(15;17)
- You have a specific genetic change called t(9;22) in your leukemia cells (confirm with trial site)
- Your AML has spread to your brain or spinal cord
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Boiclair Stephanie, MD, Northwell Health
Phone: (516) 734-8896
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Venetoclax Tolerability Rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.